



2026 CPHI Worldwide Milan



Date : 2026.10.6

Company Snapshot

67 employees | Taipei, Taiwan | Stock TPEx:4168



20+ Years in Glycobiology

Clinical-stage biopharma with integrated antibody discovery, CMC and clinical capability



GlycoSH™ Antibody Platform

Proprietary bank of antibodies against tumor-associated carbohydrate antigens



GNX1021 — Phase 1

First-in-class anti-bLeB/Y ADC, multinational trial in Japan and Taiwan



SPD8 — Phase 3 Complete

Denosumab biosimilar with positive top-line results

GlycoNex is seeking partners for clinical-stage anti-glycan antibody therapeutics and late-stage biosimilar commercialization.


2026 Achievement

Taiwan BIO Awards Emerging Company of the Year




GlycoSH Anti-Glycan Antibody Platform

A different way of targeting cancer



Unlocking tumor-associated glycan targets beyond conventional protein biomarkers



Proprietary Antibody Library

Anti-glycan antibodies owned by GlycoNex



Cancer-Associated Glycan Targets

Targets beyond conventional protein biomarkers



Partner-Ready Modalities

Applicable to ADC, bispecific, and antibody formats

Development Strategy & Pipeline

Anti-Glycan ADC Programs

GNX1021

anti-bLeB/Y MMAE ADC · GI cancers

Discovery / Lead Opt.

Preclinical

Phase 1

Phase 3 / Registration

Phase 1 ongoing (JP / TW)

GNX201-ADC

protease-activated Pro-ADC

Preclinical

GNX203

bispecific ADC

Lead optimization

Biosimilar Programs

SPD8-P / SPD8-R

denosumab biosimilar

Phase 3 complete — registration ready

SSR

psoriasis biosimilar


CMC development

GNX1021: First-in-Class ADC

FIRST-IN-CLASS ANTI-GLYCAN ADC

Anti-bLeB/Y-MMAE

- Targets tumor-associated glycan epitopes
- Designed for epithelial cancers
- Phase 1 in GI cancers (Japan & Taiwan)



Strong tumor growth inhibition in gastric cancer model

UNMET NEED in GASTRIC CANCER

EXPANDING BEYOND PROTEIN BIOMARKERS

Address glycan-positive tumors beyond conventional HER2 and CLDN18 biomarker-defined GC therapies

HER2 therapies

CLDN18 therapies

bLeB/Y — GNX1021

SYNERGISTIC TUMOR TARGETING

GLYCAN EPITOPES ON MULTIPLE TUMOR SURFACE CARRIERS

bLeB/Y glycan epitopes can be displayed across multiple tumor-associated surface carriers


Multiple surface carriers

Shared glycan epitope

Broader tumor recognition

Biosimilar Development Platform

End-to-end capability



SPD8 — Denosumab Biosimilar



Phase 3 complete · positive top-line results
Osteoporosis and cancer-related skeletal events

Open for regional licensing, distribution,
commercialization, and product supply

SSR — Autoimmune Biosimilar Candidate



CMC development stage
Biosimilar candidate for psoriasis

Open for early co-development and future
commercialization partnership

Platform open to partnering on biosimilar co-development

Partnering Opportunities



GNX1021 — Clinical-Stage ADC

Clinical collaboration, licensing, and co-development



SPD8 — Registration-Ready Biosimilar

Regional licensing, distribution, product supply, and commercialization



GlycoSH™ Antibody Library

Anti-glycan antibody discovery with partner payloads or platforms



Biosimilar Co-Development

Joint development of SSR and additional biosimilar candidates

Let's meet at CPHI Milan — Wen-Han Lee · whlee@glyconex.com.tw · +886-2-2697-4168 ext.114



GLYCONEX INC.
台灣醣聯生技醫藥



THANK YOU



Contact Information

Wen-Han Lee

Tel : +886-2-2697-4168 ext.114

Email : whlee@glyconex.com.tw